Trials / Withdrawn
WithdrawnNCT01849081
Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver
Evaluating the Efficacy of CPAP Therapy for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
We are doing this research study to evaluate whether continuous positive airway pressure (CPAP), a treatment for sleep apnea, will also help treat fatty liver disease. Sleep apnea is a disease where a person has interruptions in their breathing while they are sleep. This can lead to low oxygen levels in the blood. CPAP is a mask that delivers oxygen at high pressure to the lungs to prevent a decrease in blood oxygen levels. CPAP is a known treatment for sleep apnea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | CPAP | Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night. |
| BEHAVIORAL | LIfestyle | Subjects will undergo 12 weeks of dietary counseling. |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2019-03-01
- Completion
- 2019-03-01
- First posted
- 2013-05-08
- Last updated
- 2020-10-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT01849081. Inclusion in this directory is not an endorsement.